People on the Move
Lycera
Cancer and autoimmune biopharma company Lycera has named doctor Jeffrey Wilkins as Chief Medical Officer.
He will lead the company’s clinical programmes for first-in-class immune modulators, including its first clinical trial planned to begin in Q2 2015.
Lycera's most advanced candidate is an ATPase modulator to treat inflammatory bowel disease. A second drug, an RORgamma agonist for immuno-oncology applications, is expected to enter trials by the end of 2015.
Most recently, Wilkins served as Clinical Lead of NeXeption, a biopharmaceutical management company. Before this, he was Chief Medical Officer and Head of Medical Affairs at Ceptaris Therapeutics, where he was the lead clinician on Valchlor gel, approved for cutaneous T-cell lymphoma.
Wilkins has also served as VP, Worldwide Clinical Research, Inflammation/Oncology at Cephalon, Senior VP of Clinical Development with Ception Therapeutics, and VP of Discovery Medicine at GSK's Centre of Excellence in External Drug Discovery.